OS Therapies price target raised to $15 from $8 at Maxim
Maxim analyst Jason McCarthy raised the firm’s price target on OS Therapies (OSTX) to $15 from $8 and keeps a Buy rating on the shares. The ...
OS Therapies announces OST-HER2 trial achieves primary endpoint
OS Therapies (OSTX) announced data from a Phase 2b clinical trial of OST-HER2 – the company’s HER2-targeted immunotherapy candidate in the rare ...
How To Roll Back NVIDIA Drivers (And Why You Might Want To)
If you notice issues with visuals or performance on your PC, it may be worth rolling back your GPU drivers. Here's how to do ...